Product image of Methylphenidate Stada (Methylphenidate Hydrochloride) supplied by GNH India

Methylphenidate Stada

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Methylphenidate Stada (Methylphenidate Hydrochloride)

Methylphenidate, the active ingredient in Methylphenidate Stada, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in appropriate patient populations.

GNH India supplies Methylphenidate Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methylphenidate Stada is a central nervous system stimulant used in the management of specific neurobehavioral disorders.

  • Attention deficit hyperactivity disorder (ADHD): Improves focus, reduces hyperactivity and impulsivity in children and adults.
  • Narcolepsy: Decreases excessive daytime sleepiness and helps control cataplexy episodes.

How It Works

  • Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their respective transporters, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The enhanced dopaminergic and noradrenergic signaling improves attention, wakefulness, and executive function, which underlies its therapeutic effects in ADHD and narcolepsy.

Side Effects

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Insomnia: Difficulty falling or staying asleep.
  • Decreased appetite: Reduced desire for food, potentially leading to weight loss.
  • Headache: Mild to moderate cranial pain.
  • Stomach pain: Gastrointestinal discomfort.
  • Irritability: Mood changes and increased agitation.
  • Weight loss: Unintended reduction in body weight.

Serious or Rare Side Effects

  • Cardiovascular events: Hypertension, tachycardia, or arrhythmias.
  • Psychosis: Hallucinations or delusional thinking.
  • Severe allergic reaction: Rash, swelling, or anaphylaxis.
  • Priapism: Persistent, painful erection.
  • Motor or vocal tics: Involuntary movements or sounds.
  • Growth suppression: Reduced growth velocity in children.

Precautions & Warnings

Before prescribing Methylphenidate Stada, clinicians should consider several safety aspects.

  • Cardiovascular assessment: Evaluate heart disease history and monitor blood pressure.
  • Psychiatric screening: Assess for pre‑existing psychosis, bipolar disorder, or severe anxiety.
  • Substance abuse history: Use cautiously in patients with a history of stimulant misuse.
  • Seizure risk: Monitor patients with seizure disorders closely.
  • Growth monitoring: Track height and weight in pediatric patients.
  • Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Avoid Interactions

Methylphenidate Stada can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): May cause hypertensive crisis.
  • Sympathomimetic agents (e.g., pseudoephedrine): Risk of excessive stimulation.
  • Antihypertensive drugs: May diminish blood‑pressure‑lowering effects.

Moderate Interactions (Monitor Closely)

  • Antidepressants (SSRIs, SNRIs): Potential for serotonin syndrome.
  • Antacids: May affect drug absorption.
  • Seizure‑threshold‑lowering agents: Increased seizure risk.

Frequently Asked Questions

Methylphenidate Stada is prescribed for attention deficit hyperactivity disorder (ADHD) and narcolepsy. In ADHD, it helps improve concentration and reduce hyperactive behavior, while in narcolepsy it promotes wakefulness and reduces sudden sleep attacks.

Methylphenidate blocks the reuptake of dopamine and norepinephrine, increasing their levels in the synaptic cleft. This heightened neurotransmitter activity enhances attention, alertness, and executive function, which underlies its therapeutic benefits for ADHD and narcolepsy.

The appropriate dose of Methylphenidate Stada is determined by the prescribing clinician based on the patient’s age, weight, clinical response, and tolerability. Dosage adjustments are made during treatment to achieve optimal therapeutic effect while minimizing side effects.

Safety data for methylphenidate in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks and discuss them with the patient. Breastfeeding mothers should consider possible drug exposure to the infant and consult a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Methylphenidate Stada belongs to the stimulant class, offering rapid onset of action and proven efficacy. Compared with non‑stimulant options, it generally provides stronger symptom control but may have a higher incidence of stimulant‑related side effects. Choice of therapy depends on individual patient factors and physician judgment.

Methylphenidate Stada should be stored at ambient temperature, below 25 °C, in its original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Methylphenidate Stada is taken orally, usually once or twice daily as directed by the prescriber. Tablets should be swallowed whole with water and can be taken with or without food, depending on the specific formulation and patient preference.

Serious risks include cardiovascular events such as hypertension or tachycardia, psychiatric effects like psychosis or severe mood changes, and rare but severe allergic reactions. Patients should be monitored regularly, and any concerning symptoms should prompt immediate medical evaluation.

Methylphenidate Stada is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, or patients with severe cardiovascular disorders, uncontrolled hypertension, or a history of psychosis. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylphenidate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT